Cargando...
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells
Pancreatic carcinoma is the major clinical entity where the nucleoside analog gemcitabine is used for first-line therapy. Overcoming cellular resistance toward gemcitabine remains a major challenge in this context. This raises the need to identify factors that determine gemcitabine sensitivity in pa...
Gardado en:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3984311/ https://ncbi.nlm.nih.gov/pubmed/24556918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.28292 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|